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Lung cancer is the most common cause of cancer death in both men and women in Western countries, with a 5-year survival rate
of 15%, which is among the lowest of all cancers. The high mortality from lung cancer is due not only to the late stage diagnosis
b u ta l s ot ot h el a c ko fe ﬀective treatments even for patients diagnosed with stage I lung cancer. Therefore, there is an urgent
need to identify new markers for early diagnosis and prognosis that could serve to open novel therapeutic avenues. Proteomics
can represent an important tool for the identiﬁcation of biomarkers and therapeutic targets for lung cancer since DNA-based
biomarkersdidnotprovetohaveadequatesensitivity,speciﬁcity,andreproducibility.Inthispaperwewilldescribestudiesfocused
on the identiﬁcation of new diagnostic, prognostic, and predictive markers for lung cancer, using proteomics technologies.
1.Introduction
Lung cancer is the most common cause of cancer death
in both men and women in Western countries, accounting
for 30% of cancer-related mortality in the United States
every year [1]. The number of deaths from lung cancer is
about three times higher than that from prostate cancer
among men and about twice that from breast cancer among
women. The most important risk factor for the development
of lung cancer is smoking, with a risk in smokers on average
tenfold higher than in nonsmokers. Lung cancer is generally
divided into small-cell lung cancer (SCLC), representing
approximately 15% of cases, and non-small-cell lung cancer
(NSCLC), representing 85% of cases and including several
histological types, such as adenocarcinoma, large-cell car-
cinoma, and squamous-cell carcinoma [2]. Regardless of
subtype, the 5-year survival rate for lung cancer is among
the lowest of all cancers (approximately 15%) [1, 3]. SCLC
is highly responsive to chemotherapy and radiation therapy
but it is often widely disseminated by the time of diagnosis,
rendering the cure diﬃcult. In contrast to SCLC, NSCLC
shows a strong primary resistance to anticancer drugs. At
diagnosis, patients with NSCLC can be divided into three
groups based on the extent of the disease and the therapeutic
strategy used: the ﬁrst group of patients, accounting for
approximately 30% of cases, is diagnosed at an early disease
stageandhastumorsthataresurgicallyresectable;thesecond
group (20% of cases) includes patients with either locally
and/or regionally advanced tumors that are treated with
a combination of chemotherapy and radiotherapy; ﬁnally,
the third group (half of patients) comprises patients with
distant metastasis at the time of diagnosis. For this group
the only treatments available are chemotherapy or radiation
therapy for palliation of symptoms. Thus, it is evident
that lung cancer is a heterogeneous disease both for its
biological features and for its clinical management [2]. The
high mortality from lung cancer is due not only to the
late stage diagnosis, when cure is very unlikely, but also to2 International Journal of Proteomics
the lack of eﬀective treatments even for patients diagnosed
with stage I lung cancer, whose survival is also surprisingly
low [1]. Therefore there is a great need to identify new
markers for early diagnosis and prognosis that could open
the way for the development of new therapeutic strategies.
A number of potential biomarkers have been identiﬁed,
such as mutations in KRAS and TP53 and alterations in
expression of carcinoembryonic antigen (CEA), cytokeratin-
19 fragment (CYFRA21-1), neuron-speciﬁc enolase (NSE),
and cancer antigen-125 (CA-125). However, few have proved
to be useful in the clinic, showing low sensitivity, speciﬁcity,
and reproducibility [4, 5].
Previously, we identiﬁed a ∼100kDa protein, which
is part of a protein complex named tumor liberated
proteins (TLP), as a promising blood marker for early
diagnosis of lung cancer [5, 6]. In particular, this protein
proved to have high speciﬁcity and sensitivity for stage I
patients with NSCL. TLP might also represent a predictive
marker of cell transformation since it is expressed in
interstitial lung ﬁbrosis. Moreover, TLP showed a speciﬁc
immunogenic activity, suggesting its possible use as an
anticancer vaccine. Indeed, it is able to induce delayed
hypersensitivity reactions and to promote blastogenesis in
cultured lymphocytes from patients presensitized with TLP.
Research is ongoing to obtain the complete sequence of
TLP, by proteomics approaches, in order to achieve adequate
antigen preparations that might be used to generate assays
for early diagnosis and, possibly, a speciﬁc anticancer
vaccine.
Proteomics is becoming an increasingly important tool
for the identiﬁcation of biomarkers and therapeutic targets
for cancer. The standard proteomics techniques, namely,
two-dimensional gel electrophoresis (2DE) and mass spec-
trometry (MS), have been developing over the past three
decades, but only at the end of 90s, through the development
of high-throughput platforms, proteomics was no longer
limited to the analysis of a few proteins at a time but allowed
the simultaneous measurement of multiple protein products
and/or protein modiﬁcations (for a detailed discussion of
these methods refer to other publications [7, 8]). Therefore,
it is now possible to detect crucial molecular patterns in
malignant cells, which might indicate disease progression
or response to therapy. Moreover, proteomics can represent
an advancement over genomics because protein biomark-
ers can be a more accurate signature of a disease state
since proteins and not transcripts are the actual functional
players [9]. Indeed, mRNA levels not always reﬂect protein
expression or activity, due to a number of posttranslational
modiﬁcations such as ubiquitination, protease cleavage,
glycosylation,phosphorylation,methylation, andacetylation
[4]. Therefore, it is increasingly evident that proteome
investigations can lead to the identiﬁcation of more reliable
cancer biomarkers. For these reasons, proteomics analysis
canbeparticularlyusefultoidentifynewbiomarkersforlung
cancer, for which DNA-based biomarkers did not prove to
have adequate sensitivity, speciﬁcity, and reproducibility [4].
In this paper we will describe studies focused on the
identiﬁcation of new diagnostic, prognostic, and predictive
markers for lung cancer, using proteomics technologies. We
will discuss the most promising ﬁndings, which could be
useful to improve the management of this disease.
2. Tissue Types for Biomarker Detection
Various tissues can be used as a source of proteins for lung
cancer proteomics analyses, including cancer tissue, blood,
and pleural eﬀusions.
Surgical specimens are principally derived from NSCLC
because, as stated above, SCLC is often diagnosed when the
disease has already spread and therefore surgical samples are
rarely obtained [2]. Another limit is the fact that adjacent
to islands of tumor cells there are stromal components,
inﬂammatory inﬁltrations, and necrotic areas. Therefore,
in order to limit the confounding eﬀect of these other
tissues, it is necessary to use methods, such as laser capture
microdissection of tissue samples on microscope slides, for
isolating only cancer cells.
Blood proteomics analysis could have a great advantage
over proteomics conducted in lung cancer tissues because
blood samples are more readily accessible. Blood contains
both potential biomarkers found in biopsied cancer and
many circulating proteins generated in the diseased tissue
[4]. However, detection of low-abundance tumor proteins
in the complex and dynamic mixture of plasma proteins
can be very diﬃcult, and it is often necessary to deplete
abundant serum proteins in order to reduce this complexity.
Moreover, before searching biomarker proteins in blood, it
can be necessary to separate proteins by their characteristics,
such as glycosylation or phosphorylation, ion charges,
hydrophobicity or hydrophilicity, and molecular weights by
chromatographic methods.
Although blood is the biological ﬂuid traditionally used
inbiomarkerstudies,pleuraleﬀusionsmightbeanewsource
of more speciﬁc lung cancer markers [2]. Pleural eﬀusion
proteincompositionisverysimilartoplasmabutthevicinity
of this ﬂuid to tumor cells suggests an enrichment of tumor-
derived proteins.
3.DiagnosticBiomarkers
Since cancer is characterized by a chronic active inﬂamma-
tion state, its microenvironment frequently contains inﬁl-
trated inﬂammatory cells and proinﬂammatory cytokines.
In response to inﬂammation, acute-phase reactant proteins
(APRPs) are produced. The association between APRP
altered levels and cancer has long been established but, only
recently, proteomics studies showed that APRP alterations
are diﬀerent in distinct tumor types [10]. Therefore, APRPs
can be used as potential biomarkers for the diagnosis of
diﬀerent types of cancer. Among APRPs, the Haptoglobin
(Hp) β chain [11], serum amyloid A (SAA) [12], and
apolipoprotein A-1 (Apo A-1) [13] proteins represent novel
potential diagnostic markers for lung cancer.
Hp is a tetrameric (α2β2) glycoprotein mainly synthe-
sized in liver during inﬂammation and infection. An increase
in Hp levels has also been reported in several cancers, such
as breast cancer [14], ovarian cancer [15], pancreatic cancerInternational Journal of Proteomics 3
[16], malignant lymphoma [17], urogenital tumor [18], and
bladder cancer [19] .T h em a i nf u n c t i o no fH pi st or e m o v e
free plasma hemoglobin [20] but Hp is also involved in
angiogenesis [21] and cell migration [22]. In a recent study,
serum level of Hp has been compared in patients with
lung cancer, other types of solid cancers, and respiratory
diseases and healthy donors by liquid chromatography-
electrospray ionization-tandem mass spectrometry (LC-ESI-
MS/MS), Western blotting, and ELISA [11]. A higher level
of Hp was present in the sera of lung cancer patients
with respect to healthy controls but only the Hp β chain
showed a signiﬁcant diﬀerence between lung cancer and
other tumors. Therefore, the Hp β chain seems to be a more
speciﬁc diagnostic marker for lung cancer. However, caution
is needed when the Hp β c h a i ni st ob eu s e da sam a r k e r
to diﬀerentiate lung cancer from other respiratory diseases
because Hp β chain levels overlap between these pathologic
states.
SAA proteins are a family of apolipoproteins with several
roles, including the transport of cholesterol to the liver, the
recruitment of immune cells to inﬂammatory sites, and the
induction of enzymes degrading extracellular matrix [23].
Among the members of this family, SAA1 and SAA2 are
synthesized in response to cytokines released by activated
monocytes/macrophages. These proteins are produced pre-
dominantly by the liver but they were found at elevated
levels in several cancers [24]. Recently, SAA1 and SAA2
were proposed to be speciﬁc diagnostic markers for lung
cancer since they are expressed at higher levels in blood and
cancer tissues from patients with lung cancer compared to
samples from healthy donors and patients with other types
of cancer or respiratory diseases, as demonstrated by LC-
MS/MS, ELISA, and immunohistochemistry analyses [12].
Moreover, SAA1 and SAA2 seem to be also involved in
lung cancer metastasis, by inducing the expression of matrix
metallopeptidase-9 (MMP-9) by macrophages. Therefore,
SAA1andSAA2couldalsorepresentnewpotentialtherapeu-
tic targets for the inhibition of lung cancer metastasis.
Consistent with the upregulation of SAA1 and SAA2
in lung cancer, a decreased level of Apo A-1, an APRP
responsibleforendogenouscholesterolremovalfromtissues,
was observed in sera of adenocarcinoma patients with
respect to healthy donors [13]. In fact, following acute-phase
reaction, Apo A-1 is replaced by SAA, which becomes the
predominant apolipoprotein implicated in the removal of
cholesterol at inﬂammatory sites [25]. Therefore, together
with the increase in SAA1 and SAA2, the decrease in Apo A-1
could also be considered a potential lung cancer marker.
As stated above, due to their vicinity to tumor cells,
pleural eﬀusions could be enriched of lung cancer-related
proteins and therefore can be a useful source of biomarkers
[2]. In a recent study, the proteome of serum and pleural
eﬀusionswascomparedbetweenNSCLCpatientsandbenign
lung diseases using two-dimensional diﬀerence gel elec-
trophoresis (2D-DIGE). As expected, more potential cancer
b i o m a r k e r sw e r ef o u n di np l e u r a le ﬀusions than in serum
[26]. Among the candidate markers, the most interesting
were gelsolin, a protein possibly involved in cancer inva-
sion, the metalloproteinase inhibitor 2, implicated in lung
parenchyma disorganization, and the pigment epithelium-
derived factor (PEDF), involved in angiogenesis inhibition.
Another potential diagnostic marker found in pleural eﬀu-
sions is NPC2 (Niemann-Pick disease type C2 protein), a
protein that seems to be involved in regulating the transport
of cholesterol [27]. Although it is not clear whether NPC2
could play a role in tumor development, it was found to
be upregulated in patients with adenocarcinoma compared
with inﬂammatory pleuritis by isoelectric focusing- (IEF-)
LC-MS/MS.
Glycosilated proteins could be a potential source of
new biomarkers because they represent 50% of the secreted
proteome and serum proteins in cancer patients are known
to be further glycosylated. Therefore, glycoproteome anal-
ysis could have great advantages for cancer biomarker
discovery [4, 28]. Glycoproteomics studies, performed by
diﬀerent methods for glycoprotein fractionation (multi-
lectin chromatography or N-GP capture) followed by LC-
MS/MS, revealed potential lung cancer biomarkers, such as
plasma kallikrein (KLKB1) [29], pleural eﬀusion periostin,
multimerin-2, CD166, and lysosome-associated membrane
glycoprotein-2 (LAMP-2) [30].
It has been suggested that the diagnosis based on the
measurement of a panel of biomarkers could be more
reliable than a single marker test [31]. Consistently, Patz and
colleagues demonstrated that four markers (retinol binding
proteins and 1-antitrypsin, discovered by proteomics, and
CEA and squamous cell carcinoma antigen, previously
known to be cancer associated) have inadequate diagnostic
power when tested independently but proved clinical utility
when used in combination [32].
4.PrognosticBiomarkers
Although tumor stage is an important predictor of patient
outcome, survival of patients diagnosed with stage I lung
cancer can also be very low [1]. Thus, there is an urgent need
to understand the molecular alterations that confer a poor
prognosis and to use this information to identify the high-
risk patients to improve their management.
By combining proteomics data (obtained by 2DE, MS,
immunohistochemistry, and tissue microarray) with mRNA
microarray data, Chen et al. identiﬁed 11 components of
the glycolysis pathway as associated with poor survival
in lung adenocarcinoma [33]. Among these candidates,
phosphoglycerate kinase 1 (PGK1) was found to be strongly
predictive of patient’s survival independently of stage. PGK1
is controlled by oxygen tension, and its increased expression
might reﬂect faster growing and more hypoxic tumors.
Although PGK1 seemed to be a promising prognostic
marker, its role in lung cancer is controversial. In fact, in
a more recent study, overexpression of PGK1 was found to
limit tumor growth in mice subcutaneously injected with
the Lewis lung carcinoma cell line (LLC-1), by promoting
antitumor immunity [34]. Moreover, LLC-1 cells overex-
pressing PGK1 showed lower invasion ability and a reduced
angiogenesis induction. Therefore, the role of PGK1 in lung
cancer warrants further investigations.4 International Journal of Proteomics
Since over 90% of deaths from lung cancer are
attributable to metastases [35], key proteins involved in this
process couldrepresent important prognostic markers. It has
been reported that upregulation of annexin A3 (ANXA3), a
member of a family of calcium- and phospholipid-binding
proteins, which has been related to cancer metastasis via
promoting angiogenesis, was signiﬁcantly associated with
advanced clinical stage, lymph node metastasis, increased
relapse rate, and decreased overall survival in lung ade-
nocarcinoma, as demonstrated by 2D-DIGE, MS, Western
blotting, and immunohistochemistry [36]. Thus, given its
importantroleinlungadenocarcinomaprogression,ANXA3
might serve as a novel prognostic biomarker for this cancer.
The metastatic phenotype of lung cancerseems to be also
related to altered levels of S100A11, a member of S100 family
of proteins, which are small calcium-binding proteins that
have been implicated in prognosis and risk of metastasis in
several tumor types [37]. Comparative proteomics analysis
of two NSCLC cell lines, the nonmetastatic CL1-0 and highly
metastatic CL1-5, performed by 2DE followed by matrix-
assisted laser desorption ionization-time of ﬂight (MALDI-
TOF)/MSandMS/MSandvalidatedbyRT-PCRandWestern
blotting, revealed an upregulation of S100A11 in metastatic
CL1-5 cells [38]. Moreover, immunohistochemical analyses
in NSCLC tissues showed that upregulation of S100A11 was
signiﬁcantly associated with higher TNM stage and positive
lymph node status, indicating that S100A11 might be an
important regulatory molecule in promoting invasion and
metastasis of NSCLC.
Altered expression of S100A6, another member of the
S100 family, seems to be also implicated in NSCLC pro-
gression [39]. In particular, elevated levels of this protein,
evaluated by surface-enhanced laser desorption ionization-
(SELDI-) MS in tumor cell lysates, plasma, and pleural eﬀu-
sions and by immunohistochemistry on tissue microarrays,
showed a trend of longer survival compared with S100A6-
negative cases. Thus, although S100A6 and S100A11 belong
to the same family of proteins, they have opposite roles in
lung cancer progression. Indeed, S100A6 has been proposed
to have a proapoptotic function [40].
Cytoskeletalreorganizationisacentralprocessregulating
cell movement and metastasis, and therefore a number of
cytoskeletal proteins have been proposed as potential cancer
prognostic markers. For instance, the increased expression
of cytokeratins (CKs), a family of cytoskeletal intermediate
ﬁlaments, has been suggested to play a role in carcinogenesis,
by promoting cellular architecture reorganization during
tumor development and progression [41]. A number of
isoforms of CK 7, 8, 18, and 19 were found at higher
levels in adenocarcinoma samples compared to uninvolved
adjacent tissues, by 2DE and MS analysis. Interestingly,
speciﬁc isoforms of the four types of CK were associated
with unfavorable prognosis. In a more recent study, CK18
plasma level has been compared in patients with NSCLC and
benign lung diseases and healthy donors by ELISA assays, in
order to explore the potential diagnostic and prognostic role
of this CK in comparison with a fragment of cytokeratin-
19 (CYFRA21-1), a well-established diagnostic marker for
lung cancer [42]. Although CYFRA21-1 was a more accurate
diagnostic marker, survival analyses showed that CK18 was a
stronger prognostic factor.
Other cytoskeletal proteins found to be correlated with
a poor prognosis in lung cancer are nonmuscle myosin
IIA, a major component of the actomyosin cytoskeleton
contributing to cell contraction during migration, and
vimentin, an intermediate ﬁlament protein involved in
epithelial-mesenchymal transition, which is a process at the
basis of invasive and metastatic behavior [43].
Phosphohistidine phosphatase (PHP14) was proposed to
be another lung cancer prognostic marker, regulating cell
migration and invasion by cytoskeleton rearrangement [44].
Indeed, it has been shown that PHP14 knockdown in highly
metastatic lung cancer cells (CL1-5) inhibited migration and
invasion, whereas its overexpression in NCI H1299 cells
induced these processes. Moreover, comparative proteomics
experiments, conducted in PHP14-knockdown and control
CL1-5 cells, revealed changes in the expression of several
proteins involved in actin cytoskeletal reorganization, thus
suggesting that PHP14 prometastatic role is mediated by a
cytoskeleton rearrangement.
Finally, other potential prognostic markers involved in
cytoskeleton regulation are calmodulin, a protein suggested
to be implicated in cytoskeletal alterations during cell death,
thymosin β4, a regulator of actin polymerization whose
overexpression seems to stimulate lung tumor metastasis,
thymosin β10, and coﬁlin-1, two regulators of actin dynam-
ics [45]. These proteins, tested in combination, proved to be
useful to predict NSCLC patients’ outcome.
5. Biomarkers for Treatment Response
Chemotherapy is the standard of care for most lung cancer
patients. Since only a minority of patients beneﬁt from
any particular chemotherapy treatment, the identiﬁcation of
molecular markers predicting positive or negative clinical
outcome upon chemotherapy treatment is needed.
In a recent study, a serum peptidome proﬁling, per-
formed by MALDI-TOF-MS in patients treated with
cisplatin-gemcitabine in combination with the proteasome
inhibitor bortezomib, revealed a 13-peptide signature dis-
tinguishing, with high accuracy, sensitivity, and speciﬁcity,
patients with short versus long progression-free survival
(PFS) [46]. Moreover, a 5-peptide signature could separate
patients with a partial response versus nonresponders. Long
duration of PFS was strongly associated with tumor response
to treatment, suggesting that the survival signature is pre-
dictive of therapy outcome rather than prognostic. It has
been hypothesized that the diﬀerentially expressed peptides
are generated from common serum proteins following
cleavage by speciﬁc exopeptidases, whose diﬀerent activities
contribute to generate cancer type-speciﬁc serum peptides
[47]. Thus, blood proteins are the source of surrogate
biomarkers because these proteins are only substrates for the
real biomarkers, that is, proteases.
The epidermal growth factor receptor (EGFR) tyrosine
kinase is an important target for treatment of NSCLC, and
EGFR-inhibitor-based therapies showed promising resultsInternational Journal of Proteomics 5
[48, 49]. In particular, geﬁtinib and erlotinib are selective
inhibitors of the EGFR currently used in NSCLC treatment.
However, only a subfraction of patients respond to EGFR
inhibitors, although most NSCLC cases express EGFR.
Therefore, several studies have been focused on the identiﬁ-
cation of protein signatures to select candidate patients, who
arelikelytobeneﬁtfromtreatmentwiththeseinhibitors[50–
52]. In the study conducted by Taguchi et al. [50], serum
analysis, performed using MALDI-MS in NSCLC patients
treatedwithgeﬁtinibanderlotinib,revealedan8-peakproﬁle
as predictive of outcome. This 8-peak signature has been
commercially launched and its clinical relevance is being
validated in a phase III clinical trial [2].
6. Conclusions
Althoughproteomicsmethodsareimprovingrapidlyandthe
development of high-throughput platforms gave promising
results, at present a comprehensive proteomics signature
is still not achievable. In fact, cancer protein proﬁling
can be very complex due to the highly variable protein
concentrations, which render diﬃcult the detection of low-
abundance tumor proteins, and the extreme biochemical
diversity of proteins, with a number of diﬀerent protein
forms that exceed several hundred thousand. In most
proteomics studies the number of detectable signals is
around 1000–3000, and therefore it is clear that future
technological innovations are needed to better proﬁle cancer
cells by measuring a signiﬁcant fraction of the proteome [8].
A number of studies have been devoted to improve lung
cancer biomarker discovery by providing new technologies.
For instance, Toyama and colleagues demonstrated that
serum protein deglycosylation improves the quantitative
performance of shotgun proteomics [53]. Moreover, in a
recent study a multivariate calculation method has been
suggested as a tool to diﬀerentiate lung cancer tissues, even
in an early stage, and control tissues [54]. A further powerful
methodology in the search for novel disease biomarkers has
been proposed to be the activity-based proteomics [55].
Despite the technical diﬃculties, the list of candidate
biomarkers for lung cancer is rapidly growing. However,
there is a great need to interpret information from this data
complexity to generate biologically relevant hypotheses. In
fact, for many of the identiﬁed proteins the functional role
in lung tumorigenesis is not yet known and a solid clinical
validationisstilllacking.Nevertheless,itislikelythatsomeof
thesecandidatebiomarkerswillservetoidentifynewpossible
therapeutic strategies.
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